Raymond James Financial Services Advisors’s Co-Diagnostics CODX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-642	Closed	-$25.6K	–	3400
2023 Q4	$25.6K	Buy	642 +234	+57%	+$8.25K	﹤0.01%	3223
2023 Q3	$13K	Sell	408 -10	-2%	-$378	﹤0.01%	3221
2023 Q2	$13.9K	Sell	418 -103	-20%	-$3.94K	﹤0.01%	3199
2023 Q1	$23.1K	Buy	521 +60	+13%	+$4.81K	﹤0.01%	3171
2022 Q4	$34.9K	Sell	461 -64	-12%	-$5.99K	﹤0.01%	3114
2022 Q3	$51K	Sell	525 -29	-5%	-$4.06K	﹤0.01%	3087
2022 Q2	$93K	Buy	554 +99	+22%	+$15.1K	﹤0.01%	3024
2022 Q1	$84K	Buy	455 +25	+6%	+$5.18K	﹤0.01%	3134
2021 Q4	$115K	Buy	430 +31	+8%	+$8.13K	﹤0.01%	3103
2021 Q3	$116K	Buy	+399	New	+$116K	﹤0.01%	3097

Other funds holding CODX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Raymond James Financial Services Advisors's CODX Position: Q1 2024 in Review

Raymond James Financial Services Advisors sold out of Co-Diagnostics (CODX) in Q1 2024, closing a stake of 642 shares — an estimated $25.6K sold.

Raymond James Financial Services Advisors first reported a position in CODX in Q3 2021 and held it in 10 quarters. The position peaked at $116K in Q3 2021. 38 funds tracked by Wall St. Rank hold CODX as of Q1 2024.

Raymond James Financial Services Advisors reported no remaining Co-Diagnostics position as of Q1 2024 after selling out during the quarter.
Raymond James Financial Services Advisors sold 642 Co-Diagnostics shares in Q1 2024, an estimated $25.6K.
Raymond James Financial Services Advisors first reported a position in Co-Diagnostics in Q3 2021 and held it in 10 quarters.
Raymond James Financial Services Advisors's Co-Diagnostics position peaked at $116K in Q3 2021.
38 funds tracked by Wall St. Rank held Co-Diagnostics as of Q1 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q1 2024, filed 22 Apr 2024.